M. Dror Michaelson
Division of Hematology/Oncology
Massachusetts General Hospital
Boston
MA 02114
USA
Name/email consistency: high
- Phase II study of sunitinib in men with advanced prostate cancer. Dror Michaelson, M., Regan, M.M., Oh, W.K., Kaufman, D.S., Olivier, K., Michaelson, S.Z., Spicer, B., Gurski, C., Kantoff, P.W., Smith, M.R. Ann. Oncol. (2009)
- ASCO 2006 highlights: targeted therapy for renal cell carcinoma. Michaelson, M.D. Cancer Treat. Rev. (2007)
- Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Michaelson, M.D., Kaufman, D.S., Kantoff, P., Oh, W.K., Smith, M.R. Cancer (2006)
- Selective bladder preservation for muscle-invasive transitional cell carcinoma of the urinary bladder. Michaelson, M.D., Shipley, W.U., Heney, N.M., Zietman, A.L., Kaufman, D.S. Br. J. Cancer (2004)
- Contribution of androgen deprivation therapy to elevated osteoclast activity in men with metastatic prostate cancer. Michaelson, M.D., Marujo, R.M., Smith, M.R. Clin. Cancer Res. (2004)
- A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors. Michaelson, M.D., Ryan, D.P., Fuchs, C.S., Supko, J.G., Garcia-Carbonero, R., Paul Eder, J., Clark, J.W. Cancer (2003)
- Genitourinary malignancies. Michaelson, M.D., Smith, M.R. Cancer. Chemother. Biol. Response. Modif (2003)
- Transitional cell carcinoma of the upper uroepithelial tract. Michaelson, M.D., Kaufman, D.S., Oh, W.K. Clin. Adv. Hematol. Oncol (2003)









